share_log

Acumen Pharmaceuticals Presents First Comprehensive Clinical And Biomarker Data For Sabirnetug At American Academy Of Neurology 2024 Annual Meeting

Benzinga ·  Apr 16 20:17
  • Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker changes
  • Presentation to be featured during AAN Emerging Science Session
  • Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024

CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session...

Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment